Content Summary
Downstream processing refers to the recovery and the purification of biosynthetic pharmaceuticals from biological sources, such as a fermentation broth. Of particular interest is the production and purification of therapeutic monoclonal antibodies (mAb). This market is projected to reach a value of USD 350 billion by the end of 2027. The downstream portion of the process typically accounts for 50–80% of the production costs of mAb therapeutics (Farid, 2007; Gavara, Bibi, Sanchez, Grasselli, & Fernandez‐Lahore, 2015) in those cases where the mAb purification platforms involve at least two to three chromatographic and filtration steps (Fahrner et al., 2001; Low, O’Leary, & Pujar, 2007).
Access this content
Choose an option below
Your content has been opened.
Register to access this content
Verify your email to access this content
Code sent. Enter it in the modal
Your content has been opened.
Why do I need to verify I’m human?
Please verify you are a human before opening this content.
Your content has been opened.
The content will open in a new window. You may need to allow popups for this site.